The Daily

Generate Biomedicines Raises $400M in Largest Biotech IPO Since 2020

The AI-driven drug discovery company priced shares at $16 each in its U.S. initial public offering, marking Massachusetts' largest life sciences offering since 2020. Generate is the fifth biotechnology company to go public in February 2026, signaling renewed momentum in biotech public markets. The Flagship Pioneering-backed startup uses generative AI to design novel protein therapeutics, including antibodies and enzymes, accelerating discovery timelines from years to months. This IPO caps a strong month for biotech capital markets and reflects growing investor confidence in AI-powered drug development platforms.

Reuters, BioPharma Dive, Boston Business Journal

CAR-T Cell Therapy: Roads and Detours for Autoimmune Diseases

Following its success in eradicating malignant B cells in cancer, chimeric antigen receptor (CAR) T cell therapy is being extended to treat autoimmune diseases. This Nature Reviews Drug Discovery review (January 26, 2026) discusses the preclinical studies and ongoing clinical trials targeting B-cell-specific antigens to rapidly deplete circulating B cells, thereby reducing autoantibody formation. Early results in lupus, multiple sclerosis, and myasthenia gravis show promise, but challenges remain around safety, durability, and scalability compared to oncology applications. The review outlines key detours — including cytokine release syndrome in non-cancer patients and the need for conditioning regimens — that must be navigated before CAR-T becomes a standard autoimmune therapy.

Nature Reviews Drug Discovery

CAR-T Therapy: A New Dawn in Autoimmune Disease Treatment

This comprehensive review examines the evolving role of CAR-T cell therapy in autoimmune diseases, highlighting its ability to rapidly deplete circulating B cells and reduce autoantibody formation — the foundation for treating conditions like systemic lupus erythematosus and rheumatoid arthritis. While CAR-T has revolutionized hematological malignancies, its application in autoimmunity requires tailored approaches to minimize toxicity in non-cancer patients. The paper outlines current clinical trials and the need for optimized conditioning regimens to balance efficacy and safety.

PMC / NCBI

Netflix Walks Away From Warner Bros. Deal; Paramount Wins Bidding War

Netflix abandoned its pursuit of Warner Bros. Discovery's streaming and studio assets after the WBD board deemed a revised $31-per-share offer from Paramount-Skydance superior to Netflix's $27.75 bid. The decision triggered a rally in Netflix shares as investors cheered the company avoiding a massive capital commitment. Paramount's victory paves the way for a consolidation of legacy media assets, though regulatory approval remains uncertain. The bidding war highlights the pressures facing traditional studios to compete with streaming giants while managing debt loads.

Reuters, CNBC, The New York Times

Puglia Surges Past Santorini as 2026's Mediterranean Hotspot

Once considered Italy's quiet heel, Puglia has now drawn global travellers seeking the charm of cliff-top views, pristine beaches, and unique cultural experiences without the congestion and premium costs that have long defined Santorini's tourism scene. Official Italian tourism figures show a sustained uptick in international arrivals and occupancy rates, reinforcing Puglia's new role in 2026 travel trends. With 800 kilometers of coastline, four UNESCO World Heritage sites (including the iconic Trulli of Alberobello), and costs 30–40% lower than Tuscany, Puglia is redefining budget-conscious Mediterranean travel.

Travel and Tour World

Venice Biennale 2026: May 9 – November 22

La Biennale di Venezia will honor the late curator Koyo Kouoh by carrying out her 2026 International Art Exhibition (61st edition) exactly as she envisioned it, with the support of her family. The exhibition runs from May 9 to November 22, 2026, at the Giardini, Arsenale, and venues across Venice. Also scheduled: the International Kids' Carnival (February 7–15) and year-round events celebrating Venetian culture. This edition promises to be a poignant tribute to Kouoh's artistic vision.

La Biennale di Venezia, Tourist Italy

Murmelbahn bauen, Natur erforschen, Trampolin springen — WIENXTRA Frühlingsprogramm

WIENXTRA Kinderinfo läutet den Frühling ein mit einem bunten Programm für Kinder: Murmelbahnbau-Workshops, Naturforscher-Stationen im Botanischen Garten, und Trampolin-Action in Wiener Parks. Die kostenlosen und niederschwelligen Angebote richten sich an Familien mit Kindern von 0–13 Jahren und finden ab Anfang März statt. Besonders beliebt: die Outdoor-Events, die Bewegung und kreatives Experimentieren verbinden. Alle Termine und Anmeldungen unter wienxtra.at/kinder.

WIENXTRA Kinderinfo

Carnevale di Venezia: International Kids' Carnival — Februar 7–15

Das International Kids' Carnival in Venedig (7.–15. Februar 2026) bietet ein buntes Programm mit Workshops, Shows und kindgerechten Aktivitäten für alle Altersgruppen. La Biennale di Venezia organisiert das familienfreundliche Festival als Auftakt zum Kulturjahr 2026. Ideal für Familien, die Karneval mit Kunst und Kultur verbinden möchten — und eine gute Gelegenheit, Venedig außerhalb der Hochsaison zu entdecken.

La Biennale di Venezia, Venice Insider Guide